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Abstract
Introduction: Acute renal failure in multiple myeloma is most frequently caused by cast
nephropathy, when excess monoclonal free light chains co-precipitate with Tamm-Horsfall protein
in the distal nephron, causing tubular obstruction. The natural history of cast nephropathy after
diagnosis is unknown. This report provides supporting histological evidence that, as serum free light
chain concentrations fall, intratubular casts may resolve within weeks.
Case presentation: We report the case of a 61-year-old Caucasian woman who presented with
multiple myeloma and dialysis-dependent acute renal failure, with serum kappa free light chain
concentrations of 15,700 mg/litre (normal range 3.3 to 19.4 mg/litre). Renal biopsy demonstrated
cast nephropathy with waxy casts in distal tubules and collecting ducts. There was an interstitial
inflammatory cell infiltrate with diffuse fibrosis and tubular atrophy. Following rehydration,
chemotherapy and free light chain removal using high cut-off haemodialysis, free light chain
concentrations fell to less than 5% of the starting level (500 mg/litre). A repeat renal biopsy 6 weeks
after the first showed resolution of cast nephropathy.
Conclusion: These observations indicate that cast nephropathy can quickly resolve on rapid
reduction of monoclonal serum free light chains. This has important implications for the
development of treatment strategies aimed at improving renal recovery rates for patients in this
setting.
Introduction
Renal failure in multiple myeloma (MM) is associated
with high morbidity and mortality. Approximately 10%
of newly diagnosed patients require dialysis. Of these,
80% will not recover renal function [1,2]. The predomi-
nant cause of dialysis-dependent renal failure in this set-
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(FLCs) are freely filtered by the glomerulus, following
which they are reabsorbed and metabolised by the proxi-
mal tubule epithelium. When the burden of filtered FLC
exceeds this resorptive capacity, FLC will then pass
through into the distal nephron. Here co-precipitation
with Tamm-Horsfall protein (THP) occurs resulting in
intratubular obstruction [3-5].
The natural history of the pathology of cast nephropathy
is unknown. There has been one previous report of a fol-
low-up renal biopsy after the initial diagnostic biopsy
showing myeloma kidney [6]. This patient was treated
with chemotherapy and initially received haemodialysis,
converting to continuous ambulatory peritoneal dialysis.
The patient became dialysis-independent after 3 months
with an associated reduction in serum paraprotein con-
centration and urinary light chain excretion. A repeat
renal biopsy at 8 months showed no cast nephropathy.
Only one recent study has accurately assessed the kinetics
of FLCs in patients with severe renal failure [7]. This report
indicated that serum FLC concentrations remained ele-
vated for many weeks despite effective induction chemo-
therapy. It also showed that high cut-off haemodialysis
led to rapid reduction in serum FLCs and with effective
chemotherapy, this reduction is maintained.
We report a case of a patient with cast nephropathy which
resolved within 6 weeks after treatment with chemother-
apy and high cut-off haemodialysis.
Case presentation
A 61-year-old Caucasian woman presented to her general
practitioner complaining of feeling tired and weak. She
had previously been fit and well, and did not take any
medications. Initial investigations revealed that she was in
acute renal failure with a serum creatinine of 872 μmol/
litre and serum urea of 31.5 mmol/litre. Serum calcium
and urate levels were normal. Haemoglobin concentra-
tion was 7.8 g/dl (78 g/litre). Urine output was approxi-
mately 2 liters/day.
Serum immunofixation electrophoresis identified mono-
clonal free kappa light chains. FLC concentrations were
quantified using a serum immunoassay [8] (FREELITE,
The Binding Site, Birmingham, UK): serum kappa 15,700
mg/litre (normal range 3.3 to 19.4 mg/litre) [9], urine
kappa 2450 mg/litre, serum lambda 22.4 mg/litre (5.7 to
26.3 mg/litre) [9], kappa/lambda ratio 701 (normal
range: 0.26 to 1.65) [9]. Immunoglobulin concentrations
were: IgG 6.81 g/litre (6 to 16 g/litre), IgA 0.79 g/litre (0.8
to 4.0 g/litre) and IgM 0.38 g/litre (0.5 to 2.0 g/litre). Lytic
lesions were seen on skeletal survey. Bone marrow exam-
ination showed 90% plasma cell infiltration. Renal ultra-
sound was unremarkable. Renal biopsy demonstrated
waxy casts consistently affecting approximately 30% of
distal tubules and collecting ducts, with associated peritu-
bular inflammatory cell infiltrate (Figure 1A). There was
moderate diffuse interstitial fibrosis and tubular atrophy.
A diagnosis of multiple myeloma and acute renal failure
due to cast nephropathy was made.
For the first 4 weeks, the patient was managed with intra-
venous hydration. During this time, a 40% reduction in
serum FLC concentration to 8590 mg/litre was seen, but
she remained in severe renal failure with an eGFR of <10
ml/min/1.73 m2. Chemotherapy was then initiated with
pulsed high-dose dexamethasone. Each pulse consisted of
40 mg once daily for 4 days.
Thalidomide 100 mg daily was added 7 days later. FLC
concentrations were reduced further to 1990 mg/litre 5
days after initiation of the first pulse. FLC removal haemo-
dialysis was commenced at this point, using a high cut-off
dialyser with increased permeability to substances up to a
molecular weight of 60 kDa [7] (HCO 1100; Gambro Dia-
lysatoren GmbH, Hechingen, Germany).
Two dialysers were used in series as previously described
[7]. The patient was dialysed for 3 hours on day 1 and 6 to
8 hours on days 2 to 6. Three further dialysis sessions of 8
hours were performed from days 8 to 14. Following this,
the patient continued on a thrice weekly 4 to 6 hour dial-
ysis schedule. Figure 2 presents serum-free kappa concen-
trations pre- and post-dialysis as well as a summary of the
chemotherapy regimen. The median decrease in serum
FLC concentration was 74% (range: 35 to 88%) per dialy-
Renal biopsiesFigure 1
Renal biopsies. (A) High power haematoxylin and eosin 
stained section of the first biopsy showing hard, fractured 
casts with associated giant cell reaction. There is a peritubu-
lar inflammatory cell infiltrate, with significant interstitial 
fibrosis and tubular atrophy. (B) High power haematoxylin 
and eosin stained section of the second biopsy demonstrating 
resolution of myeloma casts. There is partial resolution of 
the interstitial inflammatory infiltrate. The degree of intersti-
tial fibrosis and tubular atrophy remained unchanged.Page 2 of 5
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replaced when indicated.
After 16 dialysis treatments, 33 days after the start of
chemotherapy, serum kappa FLC concentrations had
fallen to less than 500 mg/litre and were subsequently
maintained below this level. Despite this, the patient
remained dialysis-dependent. Another renal biopsy was
performed. This showed no evidence of myeloma casts
and partial resolution of the inflammatory infiltrate,
while the degree of diffuse moderate interstitial fibrosis
remained unchanged (Figure 1B).
Both the first and second biopsies were examined by light
microscopy in detail along their entire lengths for the
presence of casts. Both contained adequate cortical tissue.
Tubules in three randomly selected high-power fields
from each biopsy were counted. The average number of
tubules were 110 for the first biopsy and 121 for the sec-
ond biopsy per high power field.
The patient had 22 haemodialysis treatments using the
high cut-off dialyser. As FLC levels remained below 500
mg/litre, she was switched to a standard high flux sched-
ule. A further 5 days later, 8 weeks from the commence-
ment of chemotherapy, in accordance with the patient's
own wishes, haemodialysis was discontinued. Creatinine
level at this point was 650 μmol/litre.
At 1 year after discontinuation of dialysis, the patient
remains symptomatically well and the myeloma is in
remission. Her current eGFR is 8 ml/min/1.73 m2 based
on a serum creatinine of 540 μmol/litre, with a main-
tained urine output. She is clinically well with no symp-
toms of uraemia and has elected to remain independent
of dialysis until she develops clinical symptoms indicative
of uraemia.
Discussion
There are several explanations for resolution of the cast
nephropathy. First, resorption via receptor-mediated
processes by tubular epithelium and/or mononuclear
cells. This is unlikely as the casts represent solid precipi-
tates and distal tubular cells and monocytes have no
known receptors for FLC-THP aggregates. Second, tubular
epithelial and mononuclear cells might phagocytose cast
fragments. This would imply that casts become increas-
ingly friable when FLC concentrations fall below the
threshold for further cast formation. But this is not
observed histologically. Third, and most likely, tubular
cast formation is a dynamic process in patients where
there is urine flow. Driven by a high serum light chain
load, casts continually precipitate. However, in the pres-
ence of sustained glomerular ultrafiltrate, they pass
through and out of the intranephronal compartment.
Indeed, light chain casts are detected in the urine of
patients with cast nephropathy [10]. Therefore, when
serum FLC concentrations are reduced, new cast forma-
tion ceases and existing casts are flushed out of the
tubules. The two biopsies we report may reflect this
dynamic process.
At the first biopsy, the histological findings of cast neph-
ropathy, inflammatory cell infiltrate and interstitial fibro-
sis were concurrent with serum concentrations of serum
kappa FLC well above those required to produce cast
nephropathy [5]. Serum FLC concentrations dropped by
40% after initial intravenous fluid therapy, indicating that
volume contraction secondary to dehydration contrib-
uted to the very high presenting FLC concentrations.
Rehydration had both a dilutional effect as well as aiding
renal clearance, consistent with a maintained urine out-
put. Five days after commencement of the first cycle of
dexamethasone, FLC levels had fallen significantly, indi-
cating a strong tumour killing effect. Following com-
mencement of FLC removal by dialysis, the
concentrations continued to fall. Five weeks after com-
mencement of dexamethasone, serum FLC concentrations
were below 500 mg/litre, the likely minimal threshold for
the formation of casts [5].
Whilst cast nephropathy contributes to acute renal failure
in myeloma associated with high concentrations of serum
FLC, other mechanisms are important. Recent studies
have shown that monoclonal FLC are capable of inducing
cytoskeletal damage, epithelial-to-mesenchymal transi-
Serum free kappa light chain concentrationsFig re 2
Serum free kappa light chain concentrations. Changes 
in concentration with dialysis and chemotherapy with time 
are shown. Pre-dialysis and post-dialysis values are connected 
by lines. The concentration at the start of the first pulse of 
dexamethasone is also shown. The arrowheads represent 
daily doses of dexamethasone. Daily thalidomide is indicated 
by the solid line at the top of the chart.Page 3 of 5
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culture, as well as effecting the release of inflammatory
cytokines and production of hydrogen peroxide [11-13].
The degree of toxicity and tendency to direct cellular tox-
icity or cast formation has been shown to be dependent
on the clonal origin of the light chain species [11,14]. This
direct toxicity may promote the diffuse inflammation and
fibrosis that is commonly seen in patients with myeloma
kidney [12]. The effects of FLC therefore may be to con-
tribute to direct tubular damage sufficient to produce olig-
uria through tubulo-glomerular feedback loops. There
may then be proximal extension of distal casts and irre-
versible acute renal failure. The severity of acute renal fail-
ure and oliguria therefore may be a product of tubular
toxicity, tubular obstruction, dehydration and com-
pounding factors such as the use of diuretics, non-steroi-
dal anti-inflammatory agents and renin-angiotensin
system blockade. This may explain why oliguria was not a
feature in our patient.
The repeat renal biopsy showed complete resolution of
the casts and the interstitial fibrosis remained unchanged
from the first biopsy indicating that there was no progres-
sion in situ from the time of the initial biopsy. This would
be consistent with the observed rapid reduction in FLC
concentrations.
In contrast to the case described previously in the litera-
ture, our patient did not recover renal function despite
rapid, sustained reductions in FLC concentrations and the
subsequent disappearance of intratubular casts within 6
weeks of treatment. We speculate there are two reasons for
this. First, significant interstitial fibrosis was present in the
first biopsy, which developed as a result of exposure to
high levels of FLC before presentation. Second, continued
exposure to FLC even at concentrations too low to cause
cast formation contributed to ongoing inflammation.
This would be consistent with incomplete resolution of
the inflammatory infiltrate.
The patient was withdrawn from dialysis through per-
sonal choice as she was symptomatically well with no
uraemic symptoms, despite having an eGFR of 8 ml/min/
1.73 m2. This is not entirely inconsistent with current
practice in the UK, where the average eGFR at initiation of
dialysis for individuals of similar age is around 8.4 ml/
min/1.73 m2 [15].
Although chemotherapy combined with high molecular
weight cut-off haemodialysis effectively reduces the FLC
burden on the kidneys, whether renal recovery is achieved
or not may depend on the toxicity of the patient's particu-
lar light chain clone as well as prompt diagnosis and insti-
tution of treatment to reduce FLC concentrations.
Conclusion
In summary, we believe that this report provides histolog-
ical evidence that as serum FLC concentrations fall,
intratubular casts can resolve within weeks. Early diagno-
sis and treatment may facilitate reversal of acute renal fail-
ure. This observation has important implications for the
development of combined haematological and renal
treatment strategies aimed at improving renal recovery
rates in this setting.
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